SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 75 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $110,968,316 | -28.8% | 7,642,446 | +2.7% | 0.02% | -26.7% |
| Q2 2023 | $155,806,770 | +5.3% | 7,444,184 | +6.3% | 0.03% | +3.4% |
| Q1 2023 | $147,918,861 | -27.2% | 7,003,734 | -12.3% | 0.03% | -29.3% |
| Q4 2022 | $203,178,599 | +92.7% | 7,983,442 | +82.0% | 0.04% | +86.4% |
| Q3 2022 | $105,429,000 | +70.9% | 4,387,440 | +36.8% | 0.02% | +83.3% |
| Q2 2022 | $61,699,000 | +93.6% | 3,206,866 | +74.9% | 0.01% | +140.0% |
| Q1 2022 | $31,873,000 | -8.9% | 1,833,930 | +14.7% | 0.01% | -16.7% |
| Q4 2021 | $34,997,000 | +9.2% | 1,598,766 | -4.7% | 0.01% | +20.0% |
| Q3 2021 | $32,044,000 | +14.1% | 1,676,859 | +2.5% | 0.01% | 0.0% |
| Q2 2021 | $28,089,000 | -57.8% | 1,635,931 | -45.0% | 0.01% | -58.3% |
| Q1 2021 | $66,521,000 | +14.4% | 2,974,992 | +13.7% | 0.01% | +9.1% |
| Q4 2020 | $58,168,000 | +18.3% | 2,615,443 | -21.5% | 0.01% | +10.0% |
| Q3 2020 | $49,159,000 | -11.7% | 3,330,568 | -11.3% | 0.01% | -16.7% |
| Q2 2020 | $55,676,000 | +69.2% | 3,756,748 | +25.2% | 0.01% | +33.3% |
| Q1 2020 | $32,907,000 | +23.1% | 2,999,629 | -1.4% | 0.01% | +50.0% |
| Q4 2019 | $26,724,000 | +15.5% | 3,043,690 | -1.7% | 0.01% | +20.0% |
| Q3 2019 | $23,137,000 | -24.2% | 3,097,523 | -5.5% | 0.01% | -28.6% |
| Q2 2019 | $30,511,000 | +75.2% | 3,277,282 | -1.2% | 0.01% | +75.0% |
| Q1 2019 | $17,419,000 | +20.8% | 3,317,872 | +2.3% | 0.00% | 0.0% |
| Q4 2018 | $14,425,000 | -46.6% | 3,241,782 | -3.0% | 0.00% | -33.3% |
| Q3 2018 | $26,992,000 | +14.9% | 3,340,546 | -0.2% | 0.01% | +20.0% |
| Q2 2018 | $23,491,000 | -52.3% | 3,346,356 | -3.2% | 0.01% | -54.5% |
| Q1 2018 | $49,203,000 | +64.5% | 3,457,712 | +1.3% | 0.01% | +57.1% |
| Q4 2017 | $29,911,000 | -17.6% | 3,414,590 | +10.0% | 0.01% | -12.5% |
| Q3 2017 | $36,304,000 | -15.5% | 3,102,848 | +0.9% | 0.01% | -20.0% |
| Q2 2017 | $42,977,000 | +23.3% | 3,076,367 | +21.1% | 0.01% | +25.0% |
| Q1 2017 | $34,847,000 | +107.3% | 2,539,820 | +8.3% | 0.01% | +100.0% |
| Q4 2016 | $16,811,000 | -48.9% | 2,344,648 | +8.0% | 0.00% | -50.0% |
| Q3 2016 | $32,923,000 | +158.3% | 2,171,723 | +67.8% | 0.01% | +166.7% |
| Q2 2016 | $12,746,000 | -27.4% | 1,294,076 | -1.8% | 0.00% | -40.0% |
| Q1 2016 | $17,557,000 | – | 1,318,028 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |